Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

(Bloomberg) -- Wall Street just spent the week ricocheting between the macro and the mania.

Most Read from Bloomberg

SpaceX IPO Raises $75 Billion in Biggest Debut of All Time US, Iran Edge Toward Interim Deal Signing Close to G7 Next Week Xbox Plans Significant Layoffs as New CEO Plans Overhaul SpaceX Shares Close 19% Higher After Historic $75 Billion IPO Trump Insists Iran Deal Is Close After Scrapping New Strikes

Investors digested mixed inflation data, positive developments in the Middle East conflict and sharp moves in oil prices. At the same time, a scramble for SpaceX exposure spilled far beyond the company's stock sale, as investors sought alternative ways to participate in one of the most anticipated public debuts in years.

The result was a market struggling to settle on a single narrative, with investors lurching between macroeconomic developments and speculative trades. By one measure, the Nasdaq 100 this week posted its largest average intraday swings since April 2025.

SpaceX became the week's flashpoint. Retail investors submitted more than $100 billion in orders for the offering, overwhelming allocations available through brokerages. But unlike past IPO frenzies, demand did not stop at the traditional order book. Investors unable to secure shares have been looking for exposure elsewhere. That helped drive big pre-IPO inflows into funds including the $2 billion Baron First Principles ETF, while fueling activity across a growing network of alternative trading venues.

Polymarket has generated more than $25 million of volume across SpaceX-related contracts. The activity also spilled into crypto-native markets, with investors trading perpetual futures linked to the company on the decentralized platform Hyperliquid. What once would have been a straightforward IPO story increasingly played out across multiple trading venues simultaneously.

"That we are seeing a proliferation in ETFs that tie to crowd-favorite stocks speaks to moment," said Peter Atwater, the president of advisory firm Financial Insyghts. "The crowd is now speculating on its own manic impulsiveness with the most potency it can find."

More than 20 SpaceX-linked ETFs have already been filed, ranging from leveraged and inverse products to options-based strategies. A leveraged ETF tied to SpaceX surged more than 80% before grinding to a halt Friday, according to data compiled by Bloomberg and information posted on the Cboe exchange's website, citing regulatory concern. ETF issuers that once waited months after an IPO to launch related products are now racing to file almost immediately, underscoring the speed with which Wall Street moves to package speculative demand.

Story Continues

"There is room for speculating for sure, but I would rather investors invest," said Nancy Tengler, CEO at Laffer Tengler Investments, who has a long-term conviction in the company.

The products used to express speculative views are becoming large enough to influence trading in the broader market. Strategists at Nomura estimate leveraged ETFs more broadly now generate roughly $8 billion of rebalancing demand for every 1% move in the market, while options positioning contributes billions more.

Barclays Plc recently estimated that similar flows tied to major US leveraged ETFs reached a record ahead of the selloff earlier this month. Such products do not determine market direction, but they can amplify prevailing trends, turning bursts of enthusiasm — or anxiety — into larger swings.

"The speculative ecosystem also argues for bigger swings around related names, because when exposure is built through leveraged and synthetic products, rallies and reversals can both move faster than investors expect," said Chris Murphy, co-head of derivatives strategy at Susquehanna International Group.

The week's swings reflected how quickly the market's focus changed. A relatively tame consumer inflation data initially boosted risk assets. A day later, stronger producer-price data raised fresh questions on cost pressures. Meanwhile, comments from President Donald Trump on Iran repeatedly shifted expectations for the conflict and sent oil and equities in opposite directions. By Friday, hopes for a diplomatic breakthrough had helped lift stocks again.

"The on-again, off-again peace deal is driving sharp near-term moves at the index level, making it more challenging to analyze and invest at the single-stock level," said Michael O'Rourke, chief market strategist at JonesTrading. "It muddies the waters as they try to navigate the mania."

Signs of caution emerged alongside the speculative fervor. Susquehanna pointed to sizeable hedging activity in semiconductor ETFs, including large purchases of downside protection on the VanEck Semiconductor ETF. Even as investors chased growth stories, others were positioning for bigger swings ahead.

SpaceX was the week's dominant obsession. But the more consequential story is how easily investors can now participate in — and build exposure around — a trade that might once have been confined largely to institutional investors.

For Aaron Korff, a 55-year-old Florida entrepreneur who runs a vehicle transport management software company, the SpaceX offering was impossible to ignore. Korff said he has never invested in an IPO before, largely because he viewed the process as cumbersome. This time was different. He submitted his request through E-Trade on Monday and got some allocation before the market opened on Friday, though the immense demand meant he only got a quarter of his initial order.

Still, Korff said the appeal extended beyond the market frenzy surrounding the stock.

"Who cares if it goes up and down? Do you love the company? Do you believe in its future? Those are the right reasons to invest in it," he said. "Elon Musk will do anything and everything to drive the businesses forward. Look at what he has done with SpaceX so far."

--With assistance from Muyao Shen, Demetrios Pogkas and Lu Wang.

Most Read from Bloomberg Businessweek

The Bankrupting of a Mobile Home Billionaire How a Tiny British Island Fell Into an International Gambling Scandal Gen Z's Latest Career Flex: A Boardroom Seat Not Even Messi Could Deliver Soccer's American Breakthrough Ice Cream Not Decadent Enough for You? Dip It in Butter

©2026 Bloomberg L.P.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

(Bloomberg) -- Bayer AG shares are facing a make-or-break few weeks, with two upcoming court developments key to stemming a more than $60 billion wipeout in market value since the German company’s ill-fated purchase of Monsanto eight years ago.

Most Read from Bloomberg

SpaceX IPO Raises $75 Billion in Biggest Debut of All Time Xbox Plans Significant Layoffs as New CEO Plans Overhaul Trump Insists Iran Deal Is Close After Scrapping New Strikes Trump Vows New Attacks on Iran, Threatens Key Energy Targets UAE and Iran Meet Face-to-Face to Try to Deescalate Tensions

Investors are awaiting a US Supreme Court ruling on Bayer’s bid to stop tens of thousands of lawsuits claiming that Monsanto’s Roundup herbicide should have been labeled as a cancer risk. Around the same time, a fairness hearing over a separate $7.25 billion class-action settlement to resolve current and future cancer lawsuits over Roundup is also scheduled.

If most of the litigation is resolved, the stock would become more investable and could rise to €50, according to Jefferies analyst Michael Leuchten. In a downside scenario, with another double-digit billion-euro litigation provision and a multi-decade overhang, the shares could fall to €30, he wrote. Bayer closed at €35.79 on Thursday.

“The litigation overshadows everything,” said Markus Manns, portfolio manager at Frankfurt-based asset manager Union Investment, a Bayer investor. “Only once there is clarity on the litigation can the company develop a reliable financial plan regarding earnings growth, debt reduction and other priorities.”

A Bayer spokesperson said Monsanto has “a multipronged strategy” and is “confident but prepared” for all outcomes with regard to both the Supreme Court case and the class settlement agreement.

The Supreme Court is expected to rule by early July. Justices heard arguments in April, weighing a $1.25 million jury verdict won by a Missouri man who blamed Roundup for his non-Hodgkin lymphoma. Bayer contends that since US regulators didn’t require a cancer warning, federal law bars the Missouri suit and others like it.

A favorable outcome in the Supreme Court will help to ease Bayer’s legal issues because it would wipe out failure-to-warn theories that have provided the basis for big-dollar verdicts in Roundup cases. The April hearing was less positive for Bayer than some had expected, and the shares have been trending lower since then.

Listen: Bayer’s Cancer Claims Roundup at US Supreme Court: BI Podcast

Still, analysts at Bank of America Corp. recently cited a legal expert who sees a 70% probability that the court rules in Bayer’s favor. And Barclays Plc analyst Charles Pitman-King expects the company “to make significant progress in resolving the majority of its outstanding litigation overhang,” helping it to unlock its fundamental valuation.

Story Continues

Settlement Hearing

The other key milestone is over Bayer’s $7.25 billion proposal to settle thousands of current and future Roundup claims. A fairness hearing is scheduled for July 9 in state court in Missouri, but opponents of the settlement have asked for a transfer to San Francisco to get the case in front of a federal judge who has already publicly noted the deal’s flaws. Bayer objected the move and said it’s confident it has good arguments for the case to be returned to Missouri’s courts.

Potential changes to the location and, therefore, timing of that decision have also unsettled investors, who are keen to move on from the Monsanto saga.

Bayer investor Manns thinks the company is likely to get its way in at least one of the cases. “I expect that a majority, likely more than 80%, of plaintiffs will support the proposal, as the settlement terms are very favorable,” he said.

“However, if both efforts fail, then we would be looking at a significant, possibly catastrophic, setback for Bayer. The long-term financial uncertainty would remain. Investors would never know when the next €5 billion settlement payment might be required.”

Bayer has already paid more than $11 billion in Roundup settlements and still faces more than 65,000 current suits blaming its active ingredient, glyphosate, for causing non-Hodgkin lymphoma, according to securities filings. The shares are down more than 60% since the company completed the $63 billion Monsanto deal.

“Bayer’s hubristic purchase of Monsanto, with what must be viewed as woeful due diligence, has been the ultimate corporate nightmare that keeps on giving,” said Ketan Patel, a fund manager at the family office Whitefriars, which doesn’t own Bayer shares.

Patel sees risks to Bayer around both rulings, noting that a Supreme Court decision against the company “could open the floodgates in every State where Roundup was sold, and where the rules surrounding labeling are interpreted differently from State to State.”

Many are more positive on the company’s prospects. The shares have 16 buy ratings among 21 analysts tracked by Bloomberg, with an average price target that suggests more than 40% upside. For Barclays’ Pitman-King, who rates Bayer overweight, the resolution of litigation could also open the door to a possible consumer health separation in future, helping the stock achieve its estimated €53 to €60 sum-of-the-parts valuation.

Still, even if the two upcoming cases go Bayer’s way, the company has other legal battles to contend with. While Monsanto stopped supplying toxic chemicals known as polychlorinated biphenyls — or PCBs — to customers for use in their products decades ago, the company has been sued by state and local governments, school districts and individuals.

Bayer has already agreed to pay almost $2 billion in settlements in PCB cases, and potentially faces billions of dollars in exposure from a growing number of lawsuits over PCB products filed by state and local governments, school districts and individuals. It is pursuing a strategy to recoup some of its litigation costs from other companies, such as General Electric Co., that were large users of the chemicals.

Read: Bayer Faces Billions in Payouts for Decades-Old Toxic Mess

“The lesson of the last decade I’d draw is: there’s always someone in the US who wants to sue Monsanto,” said Berenberg’s Sebastian Bray. “A Supreme Court victory would be a great way of protecting Bayer, but it probably wouldn’t solve absolutely everything.”

--With assistance from Jef Feeley.

Most Read from Bloomberg Businessweek

Gen Z’s Latest Career Flex: A Boardroom Seat How a Tiny British Island Fell Into an International Gambling Scandal The Bankrupting of a Mobile Home Billionaire Ice Cream Not Decadent Enough for You? Dip It in Butter SpaceX IPO Demands Trust in Musk’s Entangled Empire

©2026 Bloomberg L.P.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

[Fleet of autonomous delivery trucks connected by digital network outside a modern warehouse at dusk] onurdongel/iStock via Getty Images

Autonomous freight trucking company Einride AB (ENRD [https://seekingalpha.com/symbol/ENRD]) began trading on Wednesday on the Nasdaq after completing a merger with special purpose acquisition company Legato Merger Corp. III (LEGT [https://seekingalpha.com/symbol/LEGT]).

Einride is a Swedish technology company focused on developing electric and autonomous freight transport solutions. Since its founding in 2016, Einride has rapidly emerged as a pioneer in the autonomous trucking industry, blending electrification, advanced AI, and data-driven logistics into a proprietary ecosystem for freight operations.

Einride (ENRD [https://seekingalpha.com/symbol/ENRD]) deploys technologies that are integrated using its data-driven operating system, Saga, to enable customers to decarbonize their operations by making an immediate shift towards digitalized, electric road freight. Notably, Einride (ENRD [https://seekingalpha.com/symbol/ENRD]) became the world’s first company to operate an autonomous, electric freight vehicle on a public road in 2019. Today, Einride leverages its suite of AI planning tools to match customer demand with optimized vehicle operations.

"With a current run-rate ARR of approximately $45 million and a total contracted base of $65 million ARR in signed customer contracts, Einride has achieved strong commercial validation with a customer base of blue-chip global transport buyers. Additionally, the Company has a base of more than $800 million of potential long-term ARR within its joint business plans, which are detailed scaling plans with customers for the continued expansion of electric and autonomous deployments. The company's operational excellence is evidenced by its 99.7% on-time performance rate, which showcases both the reliability and scale of its electric freight operations," read part of a statement from the company.

The Stockholm-based company also highlighted that it is a partner to some large companies taking the first steps together towards smart road freight, including PepsiCo (PEP [https://seekingalpha.com/symbol/PEP]), Heineken (HEINY [https://seekingalpha.com/symbol/HEINY]), DP World, GE Appliances (GE [https://seekingalpha.com/symbol/GE]), Philips, Mars, Carlsberg (CABGY [https://seekingalpha.com/symbol/CABGY]), and Lidl.

Notable early investors in the company included EQT Ventures, Maersk’s venture capital arm, IonQ, NordicNinja VC, and Barclays (BCS [https://seekingalpha.com/symbol/BCS]).

The pre-market valuation on Einride (ENRD [https://seekingalpha.com/symbol/ENRD]) was $1.35B. Shares of Einride (ENRD [https://seekingalpha.com/symbol/ENRD]) opened at $16.18 but have since settled back to $15.50.

Other companies active in autonomous truck software include Aurora Innovation (AUR [https://seekingalpha.com/symbol/AUR]), CreateAI Holdings Inc. (TSPH [https://seekingalpha.com/symbol/TSPH]), Embark Trucks, Plus Automation, Gatik, Torc Robotics, Kodiak Robotics, Waabi, Volvo Autonomous Solutions, and Waymo (GOOG [https://seekingalpha.com/symbol/GOOG]). Major OEMs such as Daimler Truck (DTRUY [https://seekingalpha.com/symbol/DTRUY]), Tesla (TSLA [https://seekingalpha.com/symbol/TSLA]), and PACCAR (PCAR [https://seekingalpha.com/symbol/PCAR]) are also heavily involved, while major tech companies like Nvidia (NVDA [https://seekingalpha.com/symbol/NVDA]) and Continental (CTTAF [https://seekingalpha.com/symbol/CTTAF]) are providing AI hardware and manufacturing expertise to support mass production of autonomous trucks.

MORE ON EINRIDE AB

* Financial information for Einride AB [https://seekingalpha.com/symbol/ENRD/income-statement]

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

Barclays has removed the monthly fee for retail investors using its Direct Investing platform. The change affects existing and new customers, reducing the ongoing cost of holding investments with the bank.

For readers tracking LSE:BARC, this update lands with the stock around £4.4795. The company's share price has risen 41.3% over the past year and shown a very large gain over five years, which puts extra attention on how it competes for retail investing business.

Removing the monthly fee makes it simpler to compare Barclays Direct Investing against other providers that are also adjusting charges. For your own portfolio, the key questions are how this change affects your total investing costs and whether the platform's tools, service and product range match what you actually use.

Stay updated on the most important news stories for Barclays by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Barclays.LSE:BARC 1-Year Stock Price Chart

See which insiders are buying and buying and selling Barclays following this latest news.

Removing the monthly fee sits squarely in the investor-activity bucket because it changes the economics for existing and prospective retail clients rather than Barclays' core banking operations. For investors, the signal is that Barclays is willing to give up a predictable fee to stay competitive in a UK investing market where platforms such as Hargreaves Lansdown and AJ Bell regularly tweak pricing. That can matter for customer behaviour, as lower fixed costs can encourage smaller and more frequent investing, which in turn may support higher trading and asset-based revenue over time. It also ties into how Barclays monetises its growing digital banking and wealth platforms, an area that has been a focus in recent years. The move comes alongside disclosures of trading in Barclays' own shares through regulatory filings, which keeps attention on how the bank allocates capital between returning cash to shareholders and investing in client-facing offerings like Direct Investing.

How This Fits Into The Barclays Narrative

Fee removal aligns with the push into digital banking and wealth offerings by making the Direct Investing platform more attractive for long-term client relationship growth. If pricing pressure intensifies across UK investment platforms, this kind of fee reduction could test Barclays' cost control efforts and margin discipline highlighted in the narrative. The narrative focuses heavily on corporate, investment banking and small-business growth, while this step in retail investing fees may not yet be fully reflected in expectations for how the group builds wealth-management revenue.

Story Continues

Knowing what a company is worth starts with understanding its story.Check out one of the top narratives in the Simply Wall St Community for Barclays to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

⚠️ Lower platform fees increase competitive pressure on profitability if rivals such as Lloyds or NatWest respond with further price cuts or if customers do not offset the lost charges with higher activity. ⚠️ Analysts already flag three risks around funding quality and bad loans, so any squeeze on non-interest income from fee cuts leaves less room for error if credit costs or funding expenses worsen. 🎁 A more cost-efficient Direct Investing offer can support stronger client retention and higher assets over time, which lines up with efforts to improve returns from UK retail and wealth operations. 🎁 Removing a visible fixed fee may make Barclays more competitive against low-cost platforms, which could help the bank capture customers who value a single provider for banking, cards and investing.

What To Watch Going Forward

Investors should watch whether lower fees translate into higher account openings, larger assets on the Direct Investing platform and greater cross-selling into Barclays' wider banking and credit products. The mix of fee-based income versus trading commissions will be important, as will any commentary on how the change affects overall UK retail profitability. It is also worth tracking how competitors adjust pricing and whether regulators comment on fee structures across UK investing platforms, as this will shape how sustainable these terms are for Barclays.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Barclays, head to the community page for Barclays to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BARC.L.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Der Gastgeber der Morning Brief, Julie Hyman, begrüßt den Yahoo Finance Breaking News Reporter Jake Conley und den Opening Media CEO Phil Rosen im Programm, um zu diskutieren, wie man das Markterholung nach dem Freitagssell-off und schnellen V-förmigen Wiederaufschwung der Halbleiteraktien nutzen kann. Ein Marktstratege empfiehlt, lang zu gehen und nichts zu tun, da er sehr bullisch ist und denkt, dass die einfachste Spielart in den letzten Jahren darin bestand, lang zu gehen und dann nichts zu tun. Er glaubt auch, dass seine AI-Agenten ähnliche Longs finden, selbst nach dem letzten Sell-off.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

(Bloomberg) -- GSK Plc agreed to buy Nuvalent Inc. in a deal valued at $10.6 billion (7.9 billion pounds), adding a biotech firm that's developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise.

Most Read from Bloomberg

House Republican Says Hegseth's D-Day Remarks 'Inappropriate' LA Mayor Race Flips as Socialist Beats Reality TV Star Pratt Trump Says He, Not Congress, Is in Charge of Kennedy Center in Reversal Trump's $100,000 H-1B Visa Application Fee Rejected by Judge Chip Stocks Rally in AI Trade Revival After Plunge: Markets Wrap

GSK will pay $124 a share in cash for Nuvalent, according to a statement Tuesday, a 40% premium over the Cambridge, Massachusetts-based company's closing share price on Monday. It marks a significant expansion of GSK's cancer portfolio, which has been slowly growing since the British drugmaker returned to the disease space in 2019, as well as the first major acquisition for Chief Executive Officer Luke Miels.

Since taking over at the start of this year, Miels has been working to revitalize GSK, which doesn't have a history of risk-taking and has long struggled to allay investors' fears about the drugs it has in development.

GSK shares fell as much as 3% in early trading in London. The stock is up by around 23% over the past 12 months.

Nuvalent designs precisely-targeted therapies for oncology patients including lung cancer. Its shares have declined by 12% this year, giving it a market value of almost $7 billion.

Two of the medicines GSK is acquiring are in late-stage trials, with the US Food and Drug Administration expected to decide on regulatory approval later this year. Both could be blockbuster medicines if approved, GSK said.

The Nuvalent deal won't impact GSK's guidance for the year, and it's expected to contribute to revenue growth from 2027, according to the statement.

The two leading drugs from Nuvalent treat non-small-cell lung cancer patients that have specific mutations. These mutations usually affect people who didn't smoke.

The fortunes of GSK and rival British drugmaker AstraZeneca Plc diverged in 2014 as Astra CEO Pascal Soriot worked to make the company a cancer drug powerhouse.

GSK meanwhile divested its oncology portfolio in an asset swap with Novartis in 2014. Miels, a protégé of Soriot, left Astra acrimoniously, with the company suing him in 2017, alleging he was in violation of his employment agreement. The two companies settled, with Miels joining GSK later that year.

Story Continues

Well-liked by investors, the pick of Australian Miels to succeed Emma Walmsley as CEO was seen as a move that could rejuvenate GSK. The drugmaker, known for its vaccines, has focused on immunology and HIV as vaccine sales have slowed.

In January, GSK agreed on a $2.2 billion deal to buy US biotech Rapt Therapeutics, which develops treatments for inflammatory and immunologic diseases. The firm secured a pulmonary hypertension drug in another transaction.

The Nuvalent purchase is expected to be completed by the third quarter, pending regulatory approvals. The transaction will be funded mainly through new and existing debt facilities plus cash and won't affect GSK's credit rating, the company said.

--With assistance from Michelle F. Davis.

(Updates with shares in fourth paragraph.)

Most Read from Bloomberg Businessweek

Chinese Diners Will Wait Five Hours for This Conveyor-Belt Sushi SpaceX IPO Forces Investors to Bet on Musk's Entangled AI Empire Men in Blazers Is Coming to Take Over the World Cup Where's the Global Economic Meltdown? What Trump Delivered for Amazon

©2026 Bloomberg L.P.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Finnair hat im Mai 2026 1.092.900 Passagiere befördert mit einem Passagierauslastungsgrad von 77,6 %. Für das laufende Jahr bis Mai 2026 beförderte die Gesellschaft 4.954.400 Passagiere mit einem Passagierauslastungsgrad von 77,9 % auf 16.308,5 Millionen verfügbaren Sitzkilometern und 12.711,4 Millionen erzielten Revenue-Passagierkilometern. Finnair hat seine 2026-Prognose bestätigt, bei der ein Umsatz zwischen €3,3 Milliarden und €3,4 Milliarden und ein vergleichbares Betriebsergebnis von €120 Millionen bis €190 Millionen erwartet wird. Die Gesellschaft plant eine Kapazitätssteigerung um etwa 3 % in 2026.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die Banken beginnen, ihre Personalbeschaffung neu zu denken, da künstliche Intelligenz (KI) Eintrittsrollen reduziert. Die Firma JPMorgan Chase & Co. hat angekündigt, dass sie die Anzahl der Junior-Analysten reduzieren wird. Andere Banken folgen diesem Beispiel und suchen nach Mitarbeitern mit technischen und datenorientierten Fähigkeiten. Die KI-Adoption könnte Produktivität und Kosten senken, aber auch Fragen zur Zukunftsfähigkeit von Führungskräften aufwerfen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Kreditwürdige Unternehmen wie DoubleLine Capital LP und Oaktree Capital Management kaufen jetzt Schulden, die gut abschneiden könnten, wenn der Boom der künstlichen Intelligenz in eine Kreditkrise umschlägt. ... Während Preise und Bewertungen von Anleihen noch nicht überfröhlich sind, wird der Markt zweifellos zu diesen Niveaus gelangen, wenn sich Technologieunternehmen in den kommenden Monaten oder Jahren mit Trillionen Dollar in KI investieren. ... Die Unternehmen fluten den Markt mit so viel Schulden, dass Geldanleger sie nicht ignorieren können. Die großen US-Technologiefirmen, sogenannte Hyperscaler, haben bereits mehr als 155 Milliarden Dollar an ungesicherten Anleihen weltweit verkauft, was bereits mehr als 45% ihrer gesamten Ausgabe im letzten Jahr ist, wie ein Bericht von Barclays vom 21. Mai zeigt.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die Zacks Research Daily präsentiert die besten Forschungsergebnisse unseres Analystenteams. Heute werden neue Forschungsberichte zu 16 wichtigen Aktien vorgestellt, darunter Broadcom Inc., Cisco Systems und Alibaba Group Holding Ltd.